登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD30 ligand >CDL-H524b

Human CD30 Ligand / TNFSF8 Protein, His Tag, low endotoxin (MALS verified)

分子别名(Synonym)

CD30-L,CD153,TNFSF8,CD30L,CD30LG,CD153 antigen,CD30 antigen ligand,CD30 Ligand

表达区间及表达系统(Source)

Human CD30 Ligand Protein, His Tag (CDL-H524b) is expressed from human 293 cells (HEK293). It contains AA Gln 63 - Asp 234 (Accession # P32971-1).

Predicted N-terminus: His

Request for sequence

蛋白结构(Molecular Characterization)

CD30 ligand Structure

This protein carries a polyhistidine tag at the N-terminus

The protein has a calculated MW of 21.5 kDa. The protein migrates as 30-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

CD30 ligand SDS-PAGE

Human CD30 Ligand Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

CD30 ligand SEC-MALS

The purity of Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) is more than 95% and the molecular weight of this protein is around 60-83 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

CD30 ligand ELISA

Immobilized Human CD30 Protein, Fc Tag (Cat. No. CD0-H5250) at 2 μg/mL (100 μL/well) can bind Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) with a linear range of 0.039-0.313 μg/mL (QC tested).

Protocol

CD30 ligand ELISA

Immobilized Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) at 2 μg/mL (100 μL/well) can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with a linear range of 0.6-10 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

CD30 ligand BLI

Loaded Biotinylated Human CD30, Avitag,His Tag (Cat. No. CD0-H82E6) on SA Biosensor, can bind Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) with an affinity constant of 132 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

活性(Bioactivity)-FACS

CD30 ligand FACS

FACS analysis shows that Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) can bind to K562-CD30 cells surface CD30. The concentration of Human CD30 Ligand is 3 μg/mL (Routinely tested).

Protocol

CD30 ligand FACS

FACS analysis shows that the binding of Human CD30 Ligand Protein, His Tag (Cat. No. CDL-H524b) to K562-CD30 cells surface CD30 was inhibited by increasing concentration of neutralizing anti-CD30 antibody. The concentration of Human CD30 Ligand used is 3 μg/mL. The IC50 is 0.2401 μg/mL (Routinely tested).

Protocol

 

背景(Background)

CD30 ligand (CD30L) and CD30 are interacting cellsurface glycoproteins that are members of the tumour necrosis factor (TNF) and tumour necrosis factor receptor
(TNFR) superfamilies. In humans, CD30L is expressed at high levels on activated T cells. There is conflicting evidence with regard to cell surface expression of CD30L on primary human B cells. An initial report of constitutive CD30L expression on peripheral blood B cells33 has not been substantiated.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD30 ligand靶点信息
英文全称:Tumor necrosis factor ligand superfamily member 8
中文全称:肿瘤坏死因子配体超家族成员8
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:临床前
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定